Tags: Government Relations

SOCMA Seeks Member Input on Chinese-origin Medical-Care Products

The Office of the U.S. Trade Representative (USTR) has announced that USTR is requesting public comments by June 25, 2020 on further modifications to remove Section 301 duties from additional Chinese-origin medical-care products, including pharmaceuticals and chemicals to make pharmaceuticals. SOCMA will submit comments to the docket and as such, requests input from members via the SOCMA 301 COVID-19 Data Sheet (page 3) for inclusion in SOCMA 301 COVID-19 Comments.

March 31, 2020

TSCA CBI Substantion

The U.S. Environmental Protection Agency has finalized its procedural rule for the review of TSCA CBI claims. This guidance document outlines and addresses the substantiation requirements for manufacturers and processors who seek to maintain CBI claims for specific chemical identities listed on the confidential portion of the TSCA Inventory.

March 18, 2020

FAQ: TSCA Risk Evaluation Fees

The following frequently asked questions address fee requirements for manufacturers and importers identified in preliminary lists as fee-obligated entities for the next 20 high priority chemical substances undergoing Toxic Substances Control Act (TSCA) risk evaluations by U.S. Environmental Protection Agency (EPA).

February 26, 2020

SOCMA Comments to U.S. EPA: TSCA New Chemical Determinations

SOCMA appreciates the opportunity to submit comments on the U.S. Environmental Protection Agency’s framework document entitled: “TSCA New Chemical Determinations: A Working Approach for Making Determinations under TSCA Section 5”.

February 18, 2020